TOP TEN perturbations for NP_690593 (Homo sapiens)

Organism: Homo sapiens
Gene: NP_690593
Selected probe(set): 35150_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NP_690593 (35150_at) across 6593 perturbations tested by GENEVESTIGATOR:

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):5.124689
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):5.0546513
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):4.005742
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):3.5743923
Number of Samples:5 / 7
Experimental E. coli study 2
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

dendritic cell study 6 (CpG A) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):2.9970884
Number of Samples:7 / 8
Experimental dendritic cell study 6 (CpG A)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

CBFA2T3 depletion; IKKb(EE) overexpression study 1 / control transfected Reh cell sample

Relative Expression (log2-ratio):2.8071318
Number of Samples:2 / 2
Experimental CBFA2T3 depletion; IKKb(EE) overexpression study 1
Non-Hodgkin’s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing CBFA2T3-silencing shRNA and pRK5 vector overexpressing constitutively active form of IκB kinase β (IKKb(EE)) along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.
Control control transfected Reh cell sample
Non-Hodgkin’s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing scramled shRNA and empty pRK5 vector along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.

PMA study 6 (500ng/ml) / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):2.7619305
Number of Samples:3 / 17
Experimental PMA study 6 (500ng/ml)
Bronchial epithelial cells (NHBE) treated with tetradecanoylphorbol acetate (500ng/ml; vendor: Sigma / catalog number: P1585 / catalog name: Phorbol 12-myristate 13-acetate [16561-29-8]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:---
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):2.6886978
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

CBFA2T3 depletion; IKKb(EE) overexpression study 1 / CBFA2T3 depletion study 1

Relative Expression (log2-ratio):2.5734568
Number of Samples:2 / 2
Experimental CBFA2T3 depletion; IKKb(EE) overexpression study 1
Non-Hodgkin’s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing CBFA2T3-silencing shRNA and pRK5 vector overexpressing constitutively active form of IκB kinase β (IKKb(EE)) along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.
Control CBFA2T3 depletion study 1
Non-Hodgkin’s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing CBFA2T3-silencing shRNA and empty pRK5 vector along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.

LPS study 2 / untreated THP-1 cell sample

Relative Expression (log2-ratio):2.414878
Number of Samples:3 / 3
Experimental LPS study 2
Cultured THP-1 mononuclear cells were treated with lipopolysaccharide (1 microgram/ml) for 4 hours at 37°C. ATC code:---
Control untreated THP-1 cell sample
Cultured THP-1 mononuclear cells were cultured in basal growth media at 37°C.